Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Blastic Plasmacytoid Dendritic Cell Neoplasm and Immuno-Oncology

The BPDCN Channel on VJHemOnc is supported by Menarini and Stemline Therapeutics. The supporters have no influence over the production of the content.

View overview page
2:18
The current landscape of treatment for BPDCN
Andrew Lane • 26 Feb 2024
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:22
Interim analysis of a study evaluating pivekimab sunirine in patients with BPDCN
Naveen Pemmaraju • 3 Jun 2023
2:18
Special session highlights: adolescents and young adults with hematologic malignancies
Naveen Pemmaraju • 3 Jun 2023
3:11
Unmet needs in BPDCN and strategies to optimize care for patients
Claudio Cerchione • 12 May 2023
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023
2:29
Unmet clinical needs in BPDCN: improving diagnosis and treatment approaches
Livio Pagano • 16 Mar 2023
1:57
Updates on treatment approaches for patients with BPDCN
Giovanni Marconi • 25 Oct 2022
4:41
Novel treatment approaches in BPDCN: the promise of CD123-targeting allogeneic CAR-T cells
Marina Konopleva • 29 Sep 2022
1:07
An insight into the CADENZA study: pivekimab sunirine in patients with R/R BPDCN
Naveen Pemmaraju • 27 Aug 2022
1:23
The promise of CD123-targeted therapy in BPDCN
Naveen Pemmaraju • 27 Aug 2022
2:37
Recent advances in the treatment of BPDCN & the long-term benefits of tagraxofusp
Naveen Pemmaraju • 27 Aug 2022
1:10
Current standard of care in BPDCN
Uwe Platzbecker • 21 Jun 2022
1:17
Insights into a study evaluating tagraxofusp for the treatment of BPDCN
Uwe Platzbecker • 21 Jun 2022
2:12
Novel agents of interest for the treatment of BPDCN
Marco Herling • 12 Jun 2022
4:19
Outcomes of patients with BPDCN after alloHSCT
Hemant Murthy • 26 Apr 2022

The BPDCN Channel on VJHemOnc is supported by Menarini and Stemline Therapeutics.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The BPDCN Channel, please contact us

The content of VJHemOnc is intended for healthcare professionals